Literature DB >> 17253597

Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.

G J Gordon1, M Mani, L Mukhopadhyay, L Dong, B Y Yeap, D J Sugarbaker, R Bueno.   

Abstract

Inhibitor of apoptosis proteins (IAPs) are overexpressed by most neoplasms and promote tumour cell survival after a wide variety of apoptotic stimuli elicited via intrinsic (ie mitochondrial) and extrinsic (ie death receptor) pathways. It has previously been reported that one of these proteins, IAP-1(MIHC/cIAP2), is overexpressed in malignant pleural mesothelioma (MPM) and is responsible for a large degree of the resistance of cultured MPM cells to cisplatin. Subsequent analysis in a larger number of human tumours revealed that additional IAPs (eg IAP-2/MIHB/cIAP1, livin/ML-IAP/KIAP, survivin, and XIAP/MIHA/hILP) are also overexpressed in MPM and, with the exception of IAP-2, have expression patterns that correlate with prognosis. In the present study, potential regulatory mechanisms of IAP genes in MPM were investigated and it was found that tumour necrosis factor-alpha (TNF-alpha) can increase mRNA and protein levels of IAP-1, IAP-2, and XIAP, but not livin or survivin in MPM cell lines (n=4). It was also found that IAP gene expression levels are increased concomitantly with translocation to the nucleus of the TNF-responsive transcription factor NF-kappaB. Co-incubation of MPM cells with TNF-alpha and pyrrolidine dithiocarbamate (PDTC), an NF-kappaB inhibitor, prevented TNF-mediated up-regulation of IAP gene expression levels. In survival studies, TNF-alpha was not toxic to MPM cells at any concentration examined. However, MPM cells exposed to TNF-alpha were twice as resistant to cisplatin in dose response survival assays compared with unstimulated controls and were found to have a significantly greater fraction of surviving cells at multiple cisplatin concentrations (p<0.0087). Finally, it was found that levels of circulating TNF-alpha were statistically significantly (p=0.031) (median 312.5 pg/ml) higher in MPM patients (n=6) prior to surgical tumour debulking compared with those after surgery (median 0 pg/ml). These results when combined with previous observations by our laboratory and others strongly suggest that IAPs act synergistically with TNF family members to promote survival of MPM tumour cells after exposure to cisplatin and possibly other chemotherapeutic drugs. Copyright (c) 2007 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253597     DOI: 10.1002/path.2120

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  29 in total

1.  Regulation of colorectal cancer cell apoptosis by the n-3 polyunsaturated fatty acids Docosahexaenoic and Eicosapentaenoic.

Authors:  Anna Giros; Mike Grzybowski; Vanessa R Sohn; Elisenda Pons; Jessica Fernandez-Morales; Rosa M Xicola; Puja Sethi; Jessica Grzybowski; Ajay Goel; C Richard Boland; Miquel A Gassull; Xavier Llor
Journal:  Cancer Prev Res (Phila)       Date:  2009-07-28

2.  Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription.

Authors:  Jessy Cartier; Jean Berthelet; Arthur Marivin; Simon Gemble; Valérie Edmond; Stéphanie Plenchette; Brice Lagrange; Arlette Hammann; Alban Dupoux; Laurent Delva; Béatrice Eymin; Eric Solary; Laurence Dubrez
Journal:  J Biol Chem       Date:  2011-06-08       Impact factor: 5.157

3.  Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.

Authors:  Ying Wang; Arun K Rishi; Vineshkumar T Puliyappadamba; Sunita Sharma; Huanjie Yang; Adi Tarca; Q Ping Dou; Fulvio Lonardo; John C Ruckdeschel; Harvey I Pass; Anil Wali
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-04       Impact factor: 3.333

4.  Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice.

Authors:  Deborah A Altomare; Craig W Menges; Jianming Pei; Lili Zhang; Kristine L Skele-Stump; Michele Carbone; Agnes B Kane; Joseph R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-17       Impact factor: 11.205

Review 5.  Tumour necrosis factor and cancer.

Authors:  Frances Balkwill
Journal:  Nat Rev Cancer       Date:  2009-04-03       Impact factor: 60.716

6.  The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables.

Authors:  Gulay Turan; Ceyda Sancakli Usta; Akin Usta; Mehmet Kanter; Lema Tavli; Meric Karacan; Cetin Celik; Metin Eser
Journal:  J Mol Histol       Date:  2014-08-09       Impact factor: 2.611

7.  Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis.

Authors:  Jakob B Seidelin; Ben Vainer; Lars Andresen; Ole H Nielsen
Journal:  Virchows Arch       Date:  2007-10-31       Impact factor: 4.064

8.  Transcriptome sequencing of malignant pleural mesothelioma tumors.

Authors:  David J Sugarbaker; William G Richards; Gavin J Gordon; Lingsheng Dong; Assunta De Rienzo; Gautam Maulik; Jonathan N Glickman; Lucian R Chirieac; Mor-Li Hartman; Bruce E Taillon; Lei Du; Pascal Bouffard; Stephen F Kingsmore; Neil A Miller; Andrew D Farmer; Roderick V Jensen; Steven R Gullans; Raphael Bueno
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-26       Impact factor: 11.205

9.  Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.

Authors:  Mehmet Kanter; Gulay Turan; Ceyda Usta; Akin Usta; H Hasan Esen; Lema Tavlı; Cetin Celik; Yusuf Demirkol; Betül Kanter
Journal:  J Mol Histol       Date:  2016-01-27       Impact factor: 2.611

10.  Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target.

Authors:  Stefania Crispi; Raffaele A Calogero; Mario Santini; Pasquale Mellone; Bruno Vincenzi; Gennaro Citro; Giovanni Vicidomini; Silvia Fasano; Rosaria Meccariello; Gilda Cobellis; Simona Menegozzo; Riccardo Pierantoni; Francesco Facciolo; Alfonso Baldi; Massimo Menegozzo
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.